drugset / Trial / NCT05070312
Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants
RandomizedParallel-groupDouble-blindHealth-services research
Summary
This study is to evaluate the pharmacokinetics, immunogenicity, safety and tolerability of investigational drug MEDI3506 with single dose in Healthy Chinese participants.
Timeline
- Start
- 2021-08-23
- Primary completion
- 2022-02-07
- Completion
- 2022-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tozorakimab | Monoclonal antibody | — | — |
Indications
No indication recorded.